“In the pooled analysis using 11 trials (SGLT2i = 25,907, placebo = 20,811), there was a substantial decline in the development of ESKD in patients under SGLT2i treatment relative to the placebo group (RR = 0.70, 95% CI: 0.65 to 0.75, I2 = 0.0%, p = 0.92, ).”
GLP-1 receptor agonists were not clearly linked with end-stage renal disease in humans (Cardiovascular risk factors without established ASCVD) (HR 0.92, 95% CI 0.783–1.069).
“ESRD rates were similar at 1 year (HR 0.92; 0.783-1.069)”
HumansCardiovascular risk factors without established ASCVD1 year
GLP-1 receptor agonists were not clearly linked with end-stage renal disease in humans (compared with SGLT2 inhibitors) (HR 0.781 (95% CI 0.397-1.537), p=0.121).
Intensive blood pressure control was not clearly linked with end-stage renal disease in humans (SPRINT and ACCORD-BP participants) (HR 1.05, 95% CI 0.74-1.48).
“not for ESKD (HR 1.05; 95% CI 0.74-1.48; P for interaction = 0.71)”
End-stage renal disease is linked with lower physical activity in hemodialysis patients (-42% light PA, -77% MVPA, -73% steps).
“Age- and sex-adjusted geometric means of light-intensity PA, moderate-to-vigorous intensity PA, and steps were 42%, 77%, and 73% lower among hemodialysis patients than community-dwelling adults.”
End-stage renal disease is linked with lower muscle mass in humans (end-stage renal disease).
“Muscle mass, handgrip strength and lower limb muscle function significantly lower in the sarcopenia group and the ESRD group compared with those in the control group.”
Translational research : the journal of laboratory and clinical medicine·
All 26Fewer
Upstream
8
Blood pressure
↔no changein humans1
1 study
Blood pressure was not clearly linked with end-stage renal disease in humans (adjusted hazard ratio 0.95, 95% CI 0.80-1.15).
“after adjustment for clinical and sociodemographic factors, higher CoV was significantly associated with cardiovascular outcomes (adjusted hazard ratio 1.25, 95% CI 1.04-1.52) but not kidney outcomes (adjusted hazard ratio 0.95, 95% CI 0.80-1.15)”
Humansvisit-to-visit blood pressure variability in CKD cohort, adjusted for clinical and sociodemographic factors4.5 yearsn = 3,891
female sex was not clearly linked with end-stage renal disease in propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors (HR 1.33; 95% CI, 0.60–2.93).
“incident ESRD (HR 1.33; 95% CI, 0.60–2.93)”
Humansin propensity-matched heart failure patients with cardiac amyloidosis on SGLT2 inhibitors3 yearsn = 466
SGLT2 inhibitors lower the risk of end-stage renal disease in humans (RR = 0.70, 95% CI: 0.65 to 0.75).
“In the pooled analysis using 11 trials (SGLT2i = 25,907, placebo = 20,811), there was a substantial decline in the development of ESKD in patients under SGLT2i treatment relative to the placebo group (RR = 0.70, 95% CI: 0.65 to 0.75, I2 = 0.0%, p = 0.92, ).”
SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (continuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts) (55% reduction; HR 0.45, 95% CI 0.25–0.81).
“a profound 55% reduction in progression to ESRD (HR 0.45, 95% CI 0.25–0.81, p=0.006)”
Humanscontinuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts1 yearn = 1,104
SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).
“incident dialysis and end-stage renal disease were significantly reduced”
Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076
Journal of the Society for Cardiovascular Angiography & Interventions·
SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (compared with DPP-4 inhibitor initiation, intention-to-treat analysis) (HR 0.374, 95% CI 0.157-0.890).
“lower risk of end-stage renal disease or dialysis (HR 0.374, 95% CI 0.157-0.890)”
Humanscompared with DPP-4 inhibitor initiation, intention-to-treat analysis
SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (type 2 diabetes and liver cirrhosis) (adjusted HR 0.34, 95% CI 0.25-0.47).
“compared with DPP4i use, SGLT2i treatment was associated with significantly reduced risks of ESKD (adjusted hazard ratio [HR], 0.34; 95% CI, 0.25-0.47)”
Humanstype 2 diabetes and liver cirrhosismedian 2.3 yearsn = 24,259
SGLT2 inhibitors are associated with end-stage renal disease in humans (Hospitalized Chinese patients with chronic kidney disease; comparison with nonusers) (HR 0.26, 95% CI 0.18-0.37).
“incidence of ESKD (HR 0.26, 95% CI 0.18-0.37, p < 0.001)”
HumansHospitalized Chinese patients with chronic kidney disease; comparison with nonusers
SGLT2 inhibitors are linked with a lower risk of end-stage renal disease in humans (relative to other anti-diabetic agents) (aHR 3.62 to 19.16 for other ADAs versus SGLT2i).
“Compared to SGLT2i, all ADAs show a significantly higher risk of developing ESRD and all-cause mortality”
End-stage renal disease is linked with a higher risk of mortality in humans (asymptomatic carotid artery disease undergoing carotid intervention) (23.5% vs. 11.8%, OR 2.31 (95% CI 1.51-3.53)).
“Mortality was significantly higher in the ESRD group at both 3 years (23.5% vs. 11.8%; OR, 2.31; 95% CI, 1.51-3.53)”
End-stage renal disease is linked with a higher risk of mortality in nonoperative treatment hip fracture patients (86.84% vs 32.0%).
“The 1-year mortality rate of the observation group was considerably higher than that of the control group, which was 86.84% and 32.0%, respectively (P < .005).”
Humansin nonoperative treatment hip fracture patientsn = 113
End-stage renal disease raises the risk of mortality in humans after major lower limb amputation (peak OR 5.57).
“End stage renal disease, heart failure, frailty, and higher-level amputation were all associated with increased mortality, demonstrating peak odds ratios of 5.57, 2.14, 2.25, and 2.30, respectively.”
GLP-1 receptor agonists are associated with end-stage renal disease in humans (Cardiovascular risk factors without established ASCVD) (HR 2.12, 95% CI 1.934–2.330 at 5 years; absolute event rates remained low).
“higher among GLP-1 RA users at 3 years (HR 1.66; 1.486-1.845) and 5 years (HR 2.12; 1.934-2.330).”
HumansCardiovascular risk factors without established ASCVD5 years
GLP-1 receptor agonists are linked with a lower risk of end-stage renal disease in humans after propensity score weighting in target trial emulation (5-year risk 1.6% versus 1.9%; risk difference -0.3% (-0.6% to 0%)).
“end-stage kidney disease (5-year risk: 1.6% versus 1.9%; risk difference: -0.3% (-0.6% to 0%); HR: 0.81 (0.69-0.95))”
Humansafter propensity score weighting in target trial emulation5-year risk
GLP-1 receptor agonists lower the risk of end-stage renal disease in silico (added to SGLT2i and standard of care in simulated CKD and T2D cohort) (6.4% vs. 7.6%).
“Adding GLP-1 RA reduced ESRD incidence (6.4% vs. 7.6%) and increased QALYs (8.76 vs. 8.35) compared to SGLT2i + SC alone.”
In silicoadded to SGLT2i and standard of care in simulated CKD and T2D cohort30-year lifetime horizonn = 10,000
End-stage renal disease is associated with sarcopenia in humans (HD patients compared with euthyroid controls) (48.5 and 26.7% in HD versus 18.1 and 6.0% in controls).
“Probable and confirmed sarcopenia were more prevalent in HD patients (48.5 and 26.7%) than in controls (18.1 and 6.0%, P = 0.004).”
HumansHD patients compared with euthyroid controlsn = 101
End-stage renal disease is associated with age-related macular degeneration in humans (Receiving long-term dialysis; compared with controls without kidney disease) (HR 1.72, 95% CI 1.50–1.97).
“The hazard ratios for AMD were 1.72, 2.47, and 1.43 for the ESRD, PD, and HD cohorts”
HumansReceiving long-term dialysis; compared with controls without kidney diseasen = 27,232
Alzheimer's disease is linked with a higher risk of end-stage renal disease in humans (time-varying exposure, adjusted for clinical variables and competing risks of death) (HR 1.67, 95% CI 1.34-2.08).
“the risk of incident ESKD was higher in the AD group than in the nonAD group (hazard ratio [HR], 1.67; 95% confidence interval [CI], 1.34-2.08).”
Humanstime-varying exposure, adjusted for clinical variables and competing risks of death
End-stage renal disease is associated with Alzheimer's disease in patients with end-stage renal disease.
“the incidence of Alzheimer's disease has also been found to be higher in patients with end-stage renal disease (ESRD) than in the general population.”
End-stage renal disease is associated with frailty in humans (Prevalence assessed using objectively measured CHS criteria) (Pooled prevalence 36.8% (95% CI 29.9–44.1%)).
“More than one-third of ESRD patients were frail based on the objectively measured CHS criteria”
ReviewPrevalence assessed using objectively measured CHS criteria
End-stage renal disease is associated with bone-specific alkaline phosphatase in humans (15.57 ± 1.59 pg/mL and 17.24 ± 2.10 pg/mL).
“By contrast, levels of bone-formative markers were highest in the ESRD groups, specifically bone-specific ALP (15.57 ± 1.59 pg/mL and 17.24 ± 2.10 pg/mL for the ESRD groups with and without the exercise intervention, respectively) and P1NP (1269.12 ± 116.34 pg/mL and 1634.07 ± 174.57 pg/mL for the ESRD groups with and without the exercise intervention, respectively”
End-stage renal disease is associated with bone-specific alkaline phosphatase in humans (chronic kidney disease).
“Bone-formative marker levels (bone-specific alkaline phosphatase and procollagen type 1 amino-terminal propeptide, P1NP) were higher in ESRD patients than in non-ESRD patients”
Kidney Failure Risk Equation and Kaiser Permanente Northwest equation
↕mixedin humans1
1 study
Kidney Failure Risk Equation and Kaiser Permanente Northwest equation predicts end-stage renal disease in humans (patients with chronic kidney disease).
“have also been validated tools in being able to predict risk of end-stage kidney disease in patients with CKD.”
Canagliflozin lowers the risk of end-stage renal disease in humans (pooled from the CANVAS and CREDENCE trials) (pooled HR 0.535 (0.392-0.729); 46.5% reduction).
“Among these trial participants, canagliflozin produced a clinically meaningful, statistically significant 46.5% reduction in end-stage kidney disease.”
Human trialpooled from the CANVAS and CREDENCE trials
Among 55,263 UK Biobank participants, exposure before birth alone was linked to lower adult kidney disease risk than no rationing exposure, with a hazard ratio of 0.78.Among 55,263 UK Biobank participants, exposure before birth alone was linked to lower adult kidney disease risk than no rationing exposure, with a hazard ratio of 0.78.
Accepted, not yet published: cohort · 55,263 peopleKidney
Who was studied55,263 UK Biobank participants, against people without rationing exposure
What changedAdult kidney disease risk was lower with rationing exposure before birth alone versus no exposure (hazard ratio 0.78)
The catchOther changes around rationing’s end could account for lower kidney disease risk
An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.An observational study of 1,351 people with heart failure linked two blood protein patterns to death and adverse kidney outcomes beyond standard risk measures.